<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2694616/" ref="ordinalpos=3831&amp;ncbi_uid=1936749&amp;link_uid=PMC2694616" image-link="/pmc/articles/PMC2694616/figure/F6/" class="imagepopup">Figure 6. Activity of <span class="highlight" style="background-color:">pathway</span> module signatures in lung cancer.  From: A Genomic Strategy to Elucidate Modules of Oncogenic <span class="highlight" style="background-color:">Pathway</span> <span class="highlight" style="background-color:">Signaling</span> Networks. </a></div><br /><div class="p4l_captionBody">A. Predicted Ras and E2F3 pathway activities across a set of 74 lung tumors. Ras activity is largely absent in the squamous cell carcinomas, and present in nearly all adenocarcinomas. Conversely, E2F3 activity is high in squamous cell carcinoma but low in adenocarcinomas. The main heat maps shows the scores of the 8 E2F pathway and 20 Ras pathway signatures (rows) projected onto the subset of 36 squamous cell carcinomas and 38 adenocarcinomas (columns), respectively.B. Kaplan-Meier survival curves for E2F signature 6 and Ras signature 9 across their respective diseases. The dotted black line shows the overall survival of all patients in the data set. The red line shows only the patients with high signature scores, and the blue line shows those with low scores.</div></div>